Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 5,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $7.52, for a total transaction of $37,600.00. Following the sale, the insider directly owned 218,387 shares of the company’s stock, valued at $1,642,270.24. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.16, for a total transaction of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00.

SOPHiA GENETICS Trading Down 1.6%

Shares of NASDAQ:SOPH traded down $0.12 during trading on Friday, reaching $7.50. 193,279 shares of the company were exchanged, compared to its average volume of 223,733. The firm has a market capitalization of $629.17 million, a PE ratio of -6.52 and a beta of 0.96. The business’s fifty day simple moving average is $5.84 and its 200-day simple moving average is $5.21. SOPHiA GENETICS SA has a 12-month low of $3.10 and a 12-month high of $7.88. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Trading of SOPHiA GENETICS

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sei Investments Co. bought a new position in shares of SOPHiA GENETICS in the 1st quarter worth $1,772,000. 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS during the fourth quarter valued at about $973,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS during the fourth quarter valued at about $2,009,000. Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the first quarter valued at about $2,157,000. Finally, Royal Bank of Canada boosted its holdings in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after buying an additional 18,781 shares in the last quarter. Institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

SOPH has been the subject of several research reports. BTIG Research upped their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.